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We previously reported that the investigational multimodal antidepressant, vortioxetine,
reversed 5-HT depletion-induced memory deﬁcits while escitalopram and duloxetine did not.
The present report studied the effects of vortioxetine and the potential impact of its 5-HT1A
receptor agonist and 5-HT3 receptor antagonist properties on 5-HT depletion-induced memory
deﬁcits. Recognition and spatial working memory were assessed in the object recognition (OR)
and Y-maze spontaneous alternation (SA) tests, respectively. 5-HT depletion was induced in
female Long-Evans rats using 4-cholro-DL-phenylalanine methyl ester HCl (PCPA) and receptor
occupancies were determined by ex vivo autoradiography. Rats were acutely dosed with
vortioxetine, ondansetron (5-HT3 receptor antagonist) or ﬂesinoxan (5-HT1A receptor agonist).
The effects of chronic vortioxetine administration on 5-HT depletion-induced memory deﬁcits
were also assessed. 5-HT depletion reliably impaired memory performance in both the tests.
Vortioxetine reversed PCPA-induced memory deﬁcits dose-dependently with a minimal effec-
tive dose (MED) ≤0.1 mg/kg (∼80% 5-HT3 receptor occupancy; OR) and ≤3.0 mg/kg (5-HT1A,
5-HT1B, 5-HT3 receptor occupancy: ∼15%, 60%, 95%) in SA. Ondansetron exhibited a MED
≤3.0 μg/kg (∼25% 5-HT3 receptor occupancy; OR), but was inactive in the SA test. Flesinoxan
had a MED ≤1.0 mg/kg (∼25% 5-HT1A receptor occupancy; SA); only 1.0 mg/kg ameliorated
deﬁcits in the NOR. Chronic p.o. vortioxetine administration signiﬁcantly improved memory
performance in OR and occupied 95%, 66%, and 9.5% of 5-HT3, 5-HT1B, and 5-HT1A receptors,NP.
o.2013.07.001
261 1331;
com,
din).
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1615-HT3 antagonism and 5-HT1A agonism reverse 5-HT depletion induced memory deﬁcitsrespectively. Vortioxetine′s effects on SA performance may involve 5-HT1A receptor agonism,
but not 5-HT3 receptor antagonism, whereas the effects on OR performance may involve 5-HT3
receptor antagonism and 5-HT1A receptor agonism.
& 2013 Elsevier B.V. and ECNP. Open access under CC BY-NC-ND license.1. Introduction
Major Depressive Disorder (MDD) is a highly disabling disease
with a lifetime prevalence of 17% in the United States (Kessler
et al., 2005). Current predictions suggest that MDD will become
the second leading cause of the global disability burden by 2020
(Michaud et al., 2001). MDD-associated disability is associated
with cognitive dysfunction (Jaeger et al., 2006) across a range
of domains, including speed of processing, executive function,
attention, and memory function (Austin et al., 2001; Lee et al.,
2011). Severe cognitive impairment may predict a poor recov-
ery of everyday functioning, and a poor response to treatment
with selective serotonin (5-HT) reuptake inhibitors (SSRIs;
Jaeger et al., 2006; Dunkin et al., 2000; Withall et al., 2009).
Importantly, these cognitive dysfunctions persist after recovery
from mood dysfunction in many patients (Herrera-Guzman
et al., 2010; Kuny and Stassen, 1995; Nebes et al., 2003),
suggesting that MDD-related cognitive dysfunction is caused by
a neurobiological substrate that is independent of mood and
may be an important target for pharmacological remediation.
The central serotonergic system is believed to play a
signiﬁcant role in the pathophysiology of MDD, although the
extent of its role remains enigmatic (Charney, 1998; Heninger
et al., 1996; aan het Rot et al., 2009). Post-mortem analyses
of brains from MDD patients indicate decreased size of the
dorsal raphe nucleus, reduced brain 5-HT transporter (SERT)
availability, and elevated 5-HT turnover (Barton et al., 2008).
Furthermore, acute tryptophan depletion causes mood low-
ering in predisposed individuals and consistently impairs
memory function (Benkelfat et al., 1994; Ellenbogen et al.,
1996; Klaassen et al., 1999). Thus, 5-HT depletion may be a
useful method to model some aspects of MDD-associated
cognitive dysfunction.
Central 5-HT depletion using the irreversible tryptophan
hydroxylase inhibitor, 4-chloro-DL-phenylalanine methyl
ester HCl (PCPA), reliably induces cognitive deﬁcits in
rodents (Hritcu et al., 2007; Matsukawa et al., 1997;
Prinssen et al., 2002). We have previously observed that a
4-day PCPA regimen impaired memory in tests of recognition
and spatial working memory in rats (Pehrson et al., 2012).
Treatment with a selective serotonin reuptake inhibitor
(SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI)
had no effect on these cognitive deﬁcits at doses corre-
sponding to full occupancy of the serotonin transporter
(SERT). However, the investigational multimodal antidepres-
sant vortioxetine restored 5-HT depletion-induced memory
deﬁcits in rats. Vortioxetine functions via two modes of
action in human recombinant cell lines: (1) SERT inhibition (Ki
1.6 nM), and (2) direct modulation of serotonergic receptors,
where it acts as an antagonist at 5-HT3 (Ki 3.7 nM), 5-HT7
(Ki 19 nM), and 5-HT1D (Ki 2.9 nM) receptors, a partial agonist
at 5-HT1B receptors (Ki 33 nM), and an agonist at 5-HT1A
receptors (Ki 15 nM) (Bang-Andersen et al., 2011; Westrichet al., 2012). Based on these data, it was hypothesized that
vortioxetine′s memory-restoring effect in 5-HT depleted rats
derived from its direct pharmacological action on serotoner-
gic receptors, rather than SERT inhibition.
Previous preclinical data demonstrated that 5-HT3 receptor
antagonists (Carey et al., 1992; Fontana et al., 1995; Boast
et al., 1999; Arnsten et al., 1997; Petkov et al., 1995; Staubli
and Xu, 1995) and 5-HT1A receptor agonists (Bertrand et al.,
2001; Horiguchi and Meltzer, 2012; Depoortere et al., 2010)
are able to improve memory in some preclinical cognitive
dysfunction models. Thus, the goal of the present study was
to investigate the role of these receptors in vortioxe-
tine’s ability to remediate 5-HT depletion-induced memory
deﬁcits. Although 5-HT3 receptor antagonism improves mem-
ory function under some conditions, we hypothesized that it
would be ineffective in reversing 5-HT-depletion induced
memory dysfunction. However we hypothesized that 5-HT1A
receptor activation would contribute to improvements in these
deﬁcits in rats.2. Experimental procedures
2.1. Animals
Female adult Long-Evans rats (223–312 g; Charles River Labora-
tories, Wilmington, MA, USA) were used. Rats were group-housed,
three per cage (Rat IVC Green Line Sealsafe plus cages; Tecniplast
USA, Philadelphia, PA), in a temperature (20.6–21.6 1C) and humid-
ity (30–70%) controlled environment on a 12 h light/dark cycle
(lights on at 6 a.m.). All animals had ad libitum access to standard
rat chow and water in their home cages. Rats were housed for
approximately 1 month before initiation of experimental proce-
dures. Except for the ﬁrst week, the rats were handled once every
second day. All procedures were approved by the Lundbeck
Research USA Institutional Animal Care and Use Committee prior
to the start of experiments and were in line with the NIH Guide to
the Care and Use of Laboratory Animals.2.2. Drugs
Vortioxetine HBr (H Lundbeck A/S, Valby, Denmark) was dissolved in
20% hydroxypropyl-β-cyclodextrin (Roquette America, Keouk, IA,
USA). Flesinoxan HCl (H. Lundbeck A/S, Valby, Denmark), ondanse-
tron HCl and 4-chloro-DL-phenylalanine methy ester HCl (PCPA;
Sigma-Aldrich, St. Louis, MO, USA) were dissolved in saline. All
doses are expressed in mg or mg of base/kg body weight and
administered as a subcutaneous (s.c.) injection at 1 mL/kg, except
PCPA where 4 mL/kg was used. The doses used for each drug are
described below in the experimental design section. For chronic p.
o. vortioxetine administration experiments, vortioxetine HBr was
incorporated into Purina 5001 rodent chow at a concentration of
0.6 g/kg of food weight (Research Diets, Inc., New Brunswick, NJ,
USA). All ligands used to deﬁne nonspeciﬁc binding in ex vivo
autoradiography experiments, i.e., 5-HT, ondansetron (both Sigma-
Aldrich, St. Louis, MO, USA) and SB216641 (Tocris Bioscience,
K.G. du Jardin et al.162Minneapolis, MN, USA) were dissolved in dimethylsulfoxide (Sigma-
Aldrich).
Radioligands: [3H]LY278584 (83 Ci/mmol; 0.2 mCi/mL) was synthe-
sized at Amersham (Piscataway, NJ, USA). [3H] 8-OH-DPAT (154.2 Ci/
mmol; 1 mCi/mL) and [3H]GR125743 (79.6 Ci/mmol; 0.2 mCi/mL)
were purchased from Perkin Elmer (Waltham, MA, USA).
2.3. Behavioral assessments
Rats were pretreated with PCPA, 86 mg/kg/day (s.c.) for 4 consecutive
days, with the ﬁnal day referred to as day zero. The magnitude of
central 5-HT depletion induced by this PCPA treatment regimen was
estimated to be 97% when measured in hippocampal tissue homo-
genate (Pehrson et al., 2012). This treatment regimen was chosen in
order to (1) induce deﬁcits in cognitive function and (2) eliminate the
role of the 5-HT transporter in vortioxetine’s mechanism of action.
Rats were randomly assigned to vehicle or drug treatment groups and
a control group was included in each experiment (n=6–13 per group).
Each experiment included assessment in the object recognition (OR)
and spontaneous alternation (SA) tests, and rats were only assessed
once in each behavioral test. The rats were injected with drug or
vehicle 1 h prior to behavioral tests, i.e., prior to the information
session in the OR task and testing in the SA task. Thirty minutes prior
to each behavioral assessment, the animals were transported to the
experimental room for acclimation.
2.4. Object recognition
On the afternoon of day 0 (i.e. the ﬁnal day of PCPA injections),
each rat was given a habituation trial, where it was individually
placed in the open ﬁeld for 5 min of free exploration. On day 1 (i.e.
24 h after the ﬁnal PCPA injection), rats received acute injections
according to their experimental condition 1 h before the training
session. In the training session, each rat was re-habituated to the
open ﬁeld for 1 min. The rat was then placed in a holding cage while
two identical objects were positioned in the open ﬁeld. Subse-
quently, the rat was positioned facing the wall and allowed to freely
explore for 15 min. Upon completion, the rat was returned to its
home cage and remained in the testing room during the retention
period.
The testing session occurred 45 min after completing information
session. Two objects were again placed in the arena, one identical
to the objects used during training and one novel. Object pairs were
validated prior to use to ensure no bias existed towards one of the
objects in the pair. The position of the novel object was pseudor-
andomly assigned (left or right) and counter-balanced for each
treatment group. The rat was positioned facing the wall and was
allowed to freely explore for 3 min.
A camera recorded all behavioral sessions, which were analyzed
for track lengths using Viewer III software (Bioserve GmbH, Fort
Lee, NJ, USA). Exploration time for each object was recorded with a
stopwatch from the videos. Exploration was deﬁned as directing the
nose towards an object at a close distance or touching the object.
Sitting on the object was not considered as an exploratory behavior.
An animal was excluded from the study if it failed to accumulate a
total exploration time 46 s, failed to explore both objects,
knocked an object over, or jumped out of the arena.
2.5. Y-maze spontaneous alternations
SA testing occurred 2 days after the last PCPA dose. One hour
following acute drug treatment, each rat was placed in the center of
the Y-maze facing the division point of two arms and allowed to
freely explore the maze for 6 min. Following each rat, the maze was
thoroughly cleaned to prevent olfactory cues. The sequence of arm
entries was recorded manually from the videos. An entry was deﬁnedas a rat crossing a virtual line between the central ends of two
parallel walls with its entire body excluding the tail. An exit was
deﬁned as any part of the animal crossing the same virtual line. An
alternation was deﬁned as any three-entry-sequence of one visit to
each arm. The performance of an animal was excluded if the total
arm entries were o7 or the rat jumped out of the arena.2.6. Ex vivo autoradiography: 5-HT1A, 5-HT1B and 5-HT3
receptor occupancies
2.6.1. Tissue preparation
Ex vivo autoradiography experiments were always conducted in
behaviorally naïve animals. One hour after acute drug treatment,
PCPA treated rats were anesthetized with CO2 and euthanized by
decapitation. Brains were dissected from the skull, frozen on
powdered dry ice, and stored at 20 1C until use. For each region
of interest, 20 mm thick coronal tissue slices were cut at 20 1C
using a microtome-cryostat (Microm, Walldorf, Germany). A mini-
mum of three replicate slices per brain were included for each
experiment. Slice collection began at approximately 1.2–1.5 mm
anterior to Bregma for 5-HT1A and 5-HT1B receptor binding studies
and at 4.8 to 5.36 mm posterior to Bregma for 5-HT3 receptor
binding studies (see Section 2.8. for exact brain regions). The
sections were mounted on slides and stored in a slide-box with
desiccant pellets at 20 1C.2.6.2. General assay procedures
Procedures for each of the ex vivo autoradiography assays used in
this study followed a similar pattern. Brieﬂy, slide-boxes were
defrosted at room temperature (RT) under a constant air stream
before opening. Following a brief preincubation (in the 5-HT1B and
5-HT3 receptor assays only), slides were incubated in assay buffer
containing the tritiated radioligand corresponding to the receptor
of interest. Nonspeciﬁc binding was determined by adding a high
concentration of a non-radioactive competitor for the target of
interest. Following incubation with the radioligand, the slides were
rinsed twice in assay buffer (4 1C) and brieﬂy dipped in distilled
water (4 1C). Subsequently, the slides were air-dried for 30 min,
transferred to a vacuum desiccator and dried for an additional
60 min. Finally, slides were processed in a Beta Imager (Biospace
Lab, Paris, France) for 16–24 h depending on the radioligand used.
Detailed descriptions of the 5-HT1B and 5-HT3 receptor assay
methods were reported previously (Pehrson et al., 2013). Speciﬁc
details for each of the receptors occupancy assays are listed in
Table 1 Radioligand concentrations were chosen based on saturation
binding experiments conducted in this laboratory. Regions of
interest for each assay are detailed below under Section 2.8.2.7. Experimental design
2.7.1. Assessing vortioxetine’s effects on 5-HT depletion-
induced object recognition (OR) and SA deﬁcits
On day 1 following cessation of PCPA treatment, PCPA-treated rats
randomly received acute injections of vehicle or vortioxetine at
0.0001, 0.1, 3, or 10 mg/kg 1 h prior to the start of the information
session in OR. On day 2 following PCPA cessation, animals received
the same treatment 1 h prior to the SA test. These doses were
chosen based on known acute dose–receptor occupancy relation-
ships (Pehrson et al., 2013), and were designed to gradually add
5-HT3 receptor antagonism, 5-HT1B receptor partial agonism, and
5-HT1A receptor agonism to vortioxetine’s pharmacological actions.
Additionally, this range of vortioxetine doses encompasses those
where it has been found active in preclinical models of anxiety or
depression (2–8 mg/kg; Mørk et al., 2012).
Table 1 Methods for ex-vivo autoradiography assays for the 5-HT1A, 5-HT1B, and 5-HT3receptors. N/A—not applicable.
Target receptors 5-HT1A receptors 5-HT1B receptors 5-HT3 receptors
Preincubation buffer N/A 170 mM Tris–HCl 4 mM CaCl2 0.01% L-
ascorbic acid
50 mM Tris–HCl 150 mM
NaCl
Preincubation time N/A 1 3 min 1 5 min
Assay buffer 170 mM Tris–HCl 4 mM
CaCl2 0.01% L-ascorbic acid 10 mM
pargyline
170 mM Tris–HCl 4 mM CaCl2
0.1% L-ascorbic acid 10 mM pargyline
50 mM Tris–HCl
150 mM NaCl 4 mM
CaCl2
Radioligand [3H]8-OH-DPAT (3 nM) [3H]GR125743 (1 nM) [3H]LY278584 (2 nM)
Nonspeciﬁc binding
agent
5-HT (10 mM) SB216641 (10 mM) Ondansetron (10 mM)
Incubation time 1 h 1 h 1 h
Rinse in cold assay
buffer
2 5 min 2 5 min 2 10 min
Cold water dip Yes Yes Yes
Acquisition time 16 h 16 h 24 h
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5-HT1A receptor agonism on 5-HT depletion-induced OR and SA
deﬁcits
The goal of this experiment was to assess whether a selective 5-HT3
receptor antagonist or 5-HT1A receptor agonist affects OR or SA
performance in 5-HT depleted animals. On day 1 after PCPA
cessation, rats in the experiment addressing effects of 5-HT3
receptor antagonism received acute injections of vehicle, 0.1 mg/kg
vortioxetine, or the selective 5-HT3 receptor antagonist ondansetron
at 0.001, 3, or 300 μg/kg. The vortioxetine dose chosen here was used
because it selectively binds to 5-HT3 receptors (see Table 2, below),
and is thus the best comparison for ondansetron. Ondansetron was
used because it is the most selective 5-HT3 receptor antagonist
available (Macor et al., 2001).
Rats in the experiments addressing effects of 5-HT1A receptor
agonism received acute injections of vehicle, 10 mg/kg vortioxe-
tine, or the selective 5-HT1A receptor agonist ﬂesinoxan at doses of
0.001, 1, or 2.5 mg/kg. The 10 mg/kg vortioxetine dose was used in
this case because it occupied 5-HT1A receptors, whereas lower
doses did not. Thus 10 mg/kg vortioxetine was the most appropriate
comparison for ﬂesinoxan. Flesinoxan was used because it is a
highly selective 5-HT1A receptor agonist (Boess and Martin, 1994).
Additionally, similarly to vortioxetine, ﬂesinoxan is a full agonist at
this receptor (Schoeffter and Hoyer, 1988).
All injections were administered 1 h prior to the start of the
information session in OR. On day 2 following the last dose of PCPA,
animals received the same treatment 1 h prior to the SA test.2.7.3. Assessing the effects of chronic vortioxetine administration
on 5-HT depletion-induced OR and SA deﬁcits
The goal of this experiment was to determine whether vortioxetine
had sustained effects on OR and SA performance in 5-HT depleted
rats after chronic p.o. administration. Rats were given ad libitum
access to vortioxetine-infused food (0.6 g of vortioxetine per kg of
food weight) or a control diet (Purina 5001 rodent chow) with
exactly the same nutritional makeup for 23 days. The rats con-
sumed 7–10 g of food per 100 g of body weight per day, giving an
approximate dose of 42–60 mg/kg/day p.o. On days 18 through 21
day of vortioxetine food administration, rats received either vehicle
or PCPA injections as previously described, and were subsequently
assessed in the OR and SA tasks on days 22 and 23 of vortioxetine
food administration.
Vortioxetine-infused food was used in this experiment to achieve
chronic administration for two reasons: (1) to avoid stressinganimals by giving multiple daily vortioxetine injections, and (2) to
avoid using chronically in-dwelling osmotic minipumps, which have
previously resulted in poor vortioxetine exposure for dosing periods
greater than 3 days.2.7.4. Ex vivo autoradiography: assessing receptor occupancies
at 5-HT1A, 5-HT1B, and 5-HT3 receptors
These experiments had two goals: (1) to determine the relationship
between vortioxetine dose and occupancies at 5-HT3, 5-HT1B and 5-HT1A
receptors in 5-HT depleted animals; (2) to relate 5-HT3 or 5-HT1A
receptor occupancies for ondansetron or ﬂesinoxan to those of
vortioxetine in the acute behavioral experiments.
For all ex vivo autoradiography experiments, rats received PCPA as
described above. On the day following PCPA cessation, PCPA-treated
animals were randomly assigned to receive acute injections of vehicle,
vortioxetine (0.1, 3, or 10 mg/kg), ondansetron (0.001, 1, 3, 300, or
1000 μg/kg), or ﬂesinoxan (0.1, 1, 2.5, 10, or 25 mg/kg) as described
above. The sample size for each drug condition was set at n=3 rats,
with each rat having 3 replicate determinations per experiment.
In addition, a separate set of experiments were conducted in rats
given chronic ad libitum access as described above to vortioxetine-
infused food (0.6 g/kg of food weight, Research Diets) or control
diet for 22 days. Given that rats tend to consume the majority of
their food at night, tissue collection experiments occurred in a
separate set of animals in the morning and afternoon, to assess
whether occupancy levels remained stable over a day.2.8. Data analysis and statistical methods
Results are expressed as mean7standard error of the mean (SEM).
All statistical analyses consisted of one-way ANOVA with Newman–
Keuls post hoc tests where appropriate. Statistical signiﬁcance was
deﬁned at po0.05. GraphPad Prism version 4.02 (GraphPad soft-
ware, San Diego, CA, USA) or MATLAB (the Mathworks, Inc, Natick,
MA, USA) was used for statistical analysis and graph design. Outliers
were eliminated if Pierce’s criteria (Ross, 2003) were met.2.9. Behavioral assessments
For the OR test, the preference score (%) was deﬁned as the time
spent exploring the novel object (in seconds) divided by the total
exploration time. For the SA test, the percentage of spontaneous
K.G. du Jardin et al.164alternations was deﬁned as the number of spontaneous alternations
divided by the total number of entries minus 2.
Rotational bias was also calculated for each animal included in the
SA experiments as described in McFarland (1989). Brieﬂy, this measure
was calculated by dividing the total number of turns by 2. This value
was subtracted from the total number of left turns made. The
absolute value was taken, divided by the total number of arm entries
made, multiplied by 100, and added to 50. This yielded the percent
bias towards the preferred direction. This measure was included to
determine whether changes in the % alternation dependent measure
were better explained by effects on motor function than spatial
working memory.Figure 1 Region of interest (ROI) in the ex vivo autoradiography 5-HT
non-speciﬁc binding (right panel). The ROI included the lateral and me
Figure 2 Acute vortioxetine dose-dependently restores memory
treatment impaired performance, but acute vortioxetine restored
treatment did not signiﬁcantly reduce locomotor activity, except
PCPA treatment impaired performance, and vortioxetine improved
the total number of responses in the SA test, but vortioxetine tre
mean7SEM. Numbers contained within bars represent the sampl
signiﬁcant differences from PCPA and control, respectively (+po0.2.10. Ex vivo autoradiography
The Beta Imager outputs were quantiﬁed using β-Vision software
(Biospace Lab, Paris, France). Surface radioactivity (expressed as counts
per min/mm2, or cpm/mm2) was measured from a region of interest
(ROI) deﬁned a priori based on previous receptor mapping experiments.
The ROIs for 5-HT1B (caudate and putamen) and 5-HT3 (amygdala, and
piriform cortex) receptors have been described in detail elsewhere
(Pehrson et al., 2013). Figure 1 shows the ROI used for the 5-HT1A
receptor binding assay, which included the lateral and medial septum.
Total binding was determined by averaging surface radioactivity
from the ROIs of three replicate slices per brain. Nonspeciﬁc binding1A receptor assay. These brain slices represent total (left panel) and
dial septum, and exhibited a high degree of speciﬁc binding.
deﬁcits induced by 5-HT depletion. In the NOR test, PCPA
performance at doses higher than 0.1 mg/kg (Panel A). PCPA
after acute 10 mg/kg vortioxetine (Panel B). In the SA test,
performance above 3 mg/kg (Panel C). PCPA treatment reduced
atment did not affect this measure (Panel D). Bars represent
e size. Plus signs (+) and asterisks (n) represent statistically
05; ++po0.01; +++po0.001).
1655-HT3 antagonism and 5-HT1A agonism reverse 5-HT depletion induced memory deﬁcitswas determined by averaging surface radioactivity from brain slices in
from the nonspeciﬁc binding condition. Speciﬁc binding was deter-
mined by subtracting nonspeciﬁc binding from total binding. Subse-
quently, speciﬁc binding levels were expressed as a percentage of the
average speciﬁc binding from vehicle-treated rats. These percentages
were subtracted from 100 to obtain percent receptor occupancy.3. Results
3.1. Behavioral assessments
3.1.1. Acute vortioxetine dose–effect curve
As reported previously, repeated PCPA administration caused
signiﬁcant deﬁcits in OR performance compared to vehicle-
treated animals (F(5,53)=7.935, po0.0001; Figure 2A). Acute
vortioxetine treatment dose-dependently improved novel
object preference scores at doses above 0.1 mg/kg. Although
PCPA-treated rats had numerically lower track lengths com-
pared to controls, these decreases were not signiﬁcant,
except where animals also received 10 mg/kg vortioxetine
(F(5,53)=2.95, po0.05; Figure 2B).Figure 3 Acute ondansetron restored memory deﬁcits induced
treatment signiﬁcantly impaired NOR preference scores (Panel A
Acute treatment with ondansetron or 0.1 mg/kg vortioxetine sig
Neither ondansetron nor vortioxetine altered PCPA’s effects on
impaired alternation scores (Panel C), but did not affect total r
scores at any dose, however 0.1 mg/kg vortioxetine did improve
nor ondansetron affected total responses in the SA task. Bars rep
sample size. Plus signs (+) and asterisks (n) represent statistica
(+po0.05; ++po0.01; +++po0.001).In the SA test, repeated PCPA administration signiﬁcantly
decreased % alternations compared to control rats (F(5,54)
=4.49, po0.01; Figure 2C). Acute vortioxetine administration
signiﬁcantly improved alternation behavior compared to the
PCPA group at the 3 and 10 mg/kg doses. Interestingly, although
lower vortioxetine doses did not signiﬁcantly improve alterna-
tion behavior compared to PCPA, rats in these groups also did
not perform signiﬁcantly worse than controls. As reported
previously, PCPA treatment was associated with reductions
in the number of arm entries (F(5,54)=5.89, po0.001;
Figure 2D), which vortioxetine did not signiﬁcantly affect.
Finally, no treatments were associated with changes in response
bias (F(5,54)=0.9, n.s.; data not shown).3.1.2. Acute ondansetron dose effect curve
PCPA treatment again signiﬁcantly reduced novel object
preference scores (F(5,40)=12.18, po0.0001; Figure 3A).
Acute ondanstetron signiﬁcantly reversed this impairment
at doses above 0.001 μg/kg. Additionally, the ability of
acute 0.1 mg/kg vortioxetine to signiﬁcantly improve novel
object preference scores was replicated in this experiment.
Once again, repeated PCPA treatment signiﬁcantly reducedby 5-HT depletion in the NOR test, but not in the SA test. PCPA
) and reduced locomotor activity during the NOR test (Panel B).
niﬁcantly improved preference scores compared to PCPA alone.
locomotor activity. In the SA test, PCPA treatment signiﬁcantly
esponses. Ondansetron did not signiﬁcantly improve alternation
alternation scores compared to PCPA alone. Neither vortioxetine
resent mean7SEM. Numbers contained within bars represent the
lly signiﬁcant differences from PCPA and control, respectively
K.G. du Jardin et al.166locomotor activity (F(5,40)=3.59, po0.01; Figure 3B). Sig-
niﬁcant reductions in track length were also observed in the
0.001 μg/kg ondansetron dose and the 0.1 mg/kg vortiox-
etine dose. However at the 3 and 300 μg/kg doses of
ondansetron, no signiﬁcant differences from controls were
observed.
In the SA task, PCPA treatment signiﬁcantly impaired alter-
nation scores (F(5,47)=4.25, po0.01; Figure 3C). Acute ondan-
setron treatment did not improve the % alternation dependent
measure compared to the PCPA only group at any dose;
however the 0.001 and 3 μg/kg doses were not signiﬁcantly
different from the control group either. Although it should be
noted that the 300 μg/kg ondansetron group had signiﬁcantly
lower alternation scores compared to controls. Interestingly, in
this cohort the 0.1 mg/kg vortioxetine dose signiﬁcantly
improved alternation scores compared to the PCPA only group,
although it did not do so in the vortioxetine dose effect curve
(see above). Also differently from the acute vortioxetine dose
effect curve, PCPA treatment did not signiﬁcantly decrease the
number of arm entries, though there was a trend towards
signiﬁcance (F(5,47)=2.04, p=0.09; Figure 3D). Once again,
none of the pharmacological treatments were associated withFigure 4 Acute ﬂesinoxan restores 5-HT depletion-induced memo
signiﬁcantly impaired novel object preference scores (Panel A) an
(Panel B). Acute treatment with 1 mg/kg ﬂesinoxan or 10 mg/kg vor
PCPA alone without altering locomotor activity. PCPA treatment al
number of responses made (Panel D) in the SA test. 1 or 2.5 mg/kg ﬂ
PCPA alone and reversed the reduction in total responses induced b
signiﬁcantly improved alternation scores without affecting total re
bars represent sample size. Plus signs (+) and asterisks (*) repres
respectively (+po0.05; ++po0.01).changes in the response bias measure (F(5,47)=0.64, n.s.; data
not shown).3.1.3. Acute ﬂesinoxan dose effect curve
Repeated PCPA administration again signiﬁcantly impaired novel
object preference scores (F(5,46)=8.94, po0.0001; Figure 4A).
Acute administration of either 1 mg/kg ﬂesinoxan or 10 mg/kg
vortioxetine in PCPA-treated animals restored novel object
preference scores back to control levels. However, 0.001 or
2.5 mg/kg ﬂesinoxan did not signiﬁcantly improve OR scores. As
observed previously, 5-HT depletion signiﬁcantly decreased
locomotor behavior during the OR test session (F(5,46)=3.36,
po0.05; Figure 4B). Although track lengths in the acute
ﬂesinoxan (at 1 or 2.5 mg/kg) or 10 mg/kg vortioxetine groups
were not signiﬁcantly greater than those of the PCPA group,
neither were they signiﬁcantly lower than in control animals.
Once again, repeated PCPA treatment signiﬁcantly
reduced alternation scores in the SA task (F(5,52)=5.2,
po0.001; Figure 4C). These reductions were reversed by
ﬂesinoxan 1 or 2.5 mg/kg by vortioxetine, 10 mg/kg. The
observation that PCPA treatment signiﬁcantly reduced thery deﬁcits in the NOR and SA tests. 5-HT depletion using PCPA
d signiﬁcantly reduced locomotor activity during the NOR task
tioxetine signiﬁcantly improved preference scores compared to
so impaired alternation scores (Panel C) and reduced the total
esinoxan signiﬁcantly improved alternation scores compared to
y PCPA treatment. Acute treatment with 10 mg/kg vortioxetine
sponses. Bars represent mean7SEM. Numbers contained within
ent statistically signiﬁcant differences from PCPA and control,
1675-HT3 antagonism and 5-HT1A agonism reverse 5-HT depletion induced memory deﬁcitsfrequency of arm entries was replicated (F(5,52)=7.56,
po0.0001; Figure 4D). Flesinoxan treatment led to signiﬁ-
cant increases in arm entries (1 and 2.5 mg/kg), while
10 mg/kg vortioxetine did not. Finally, no experimental
manipulations altered response biases (F(5,52)=1.99, n.s.;
data not shown).
3.1.4. Chronic vortioxetine administration
PCPA treatment signiﬁcantly impaired novel object prefer-
ence scores (F(2,20)=5.96, po0.01; Figure 5A), which were
restored back to control levels by chronic vortioxetine.
PCPA administration did not signiﬁcantly decrease locomo-
tor behavior in this case (F(2,20)=1.18, n.s.; Figure 5B).
In the SA test, although animals treated with PCPA only or
PCPA and chronic vortioxetine displayed numerically lower
alternation scores than controls, these differences only
trended towards signiﬁcance (F(2,20)=2.99, p=0.073).
Similarly, no signiﬁcant differences between treatment
groups were observed in the total responses dependent
measure (F(2,20)=0.007, n.s), or in the response bias
measure (F(2,20)=1.02, n.s.; data not shown).
3.1.5. Receptor occupancy
Target occupancies after acute dosing are presented in Table 2.
Acute vortioxetine (0.1–10 mg/kg) treatment produced signiﬁ-
cant receptor occupancy (78–97%) at 5-HT3 receptors at all
doses tested (F(3,8)=161.96, po0.001). 5-HT1B receptor occu-
pancy was signiﬁcantly greater than vehicle at 3 and 10 mg/kg
vortioxetine (F(3,7)=163.4, po0.001), while 5-HT1A receptor
occupancy was signiﬁcantly greater than vehicle only at 10 mg/
kg vortioxetine (F(3,8)=6.67, po0.05).
Ondansetron (0.001–1000 mg/kg) produced signiﬁcant,
dose-dependent increases in 5-HT3 receptor occupancy
(F(5,12)=24.5, po0.001) at doses above 0.1 μg/kg, while
ﬂesinoxan (0.1–25 mg/kg) signiﬁcantly occupied 5-HT1A
receptors at all doses tested.
Chronic vortioxetine administration in food leads to
similar proﬁles of receptor occupancy whether measured
in the morning or afternoon. Fractional occupancies at
the 5-HT1A receptor were 9.573.5% and 1170.8% in the
morning and afternoon, respectively. 5-HT1B receptorFigure 5 Chronic vortioxetine administration blocks 5-HT depleti
PCPA induced signiﬁcant deﬁcits in preference scores in the NOR
administration. Neither PCPA nor chronic vortioxetine affected l
mean7SEM. Numbers contained within bars represent sample size.
differences from PCPA and control, respectively (+po0.05).occupancies were 6672.1% in the morning and 5071.3%
in the afternoon. Finally, occupancies at the 5-HT3 receptor
were 9570.6% and 9670.6% in the morning and afternoon,
respectively.4. Discussion
The present study demonstrated that vortioxetine reversed the
5-HT depletion-induced OR and SA deﬁcits in a dose- and test-
dependent manner. A low acute dose of 0.1 mg/kg consistently
improved memory performance in 5-HT depleted rats in the OR
test and less consistently in the SA task, while higher doses
of 3 and 10 mg/kg consistently improved performance in both
tasks. Chronic vortioxetine administration also improved 5-HT
depletion-induced deﬁcits in OR performance, but its effects
on SA are unclear due to PCPA’s lack of an effect on SA
performance in that experiment. Moreover, vortioxetine’s
memory effects were independent of the locomotor activity-
suppressing effects of 5-HT depletion, which were not changed
by vortioxetine administration. Furthermore, the 5-HT3 recep-
tor antagonist ondansetron selectively improved OR perfor-
mance without affecting the SA test. The 5-HT1A receptor
agonist ﬂesinoxan signiﬁcantly improved OR performance at the
1 mg/kg dose, restored SA performance to normal levels at
1 and 2.5 mg/kg doses, and reversed some 5-HT depletion-
induced motor deﬁcits.
We have reported elsewhere (Pehrson et al., 2012) that
the SSRI escitalopram and the SNRI duloxetine fail to restore
5-HT depletion-induced deﬁcits in the OR and SA tests at
doses corresponding to full SERT occupancy. These data
suggest that SERT inhibition is insufﬁcient to restore mem-
ory function to normal levels in 5-HT depleted animals.
Thus, vortioxetine’s effects on 5-HT depletion-induced
memory deﬁcits are most likely mediated via direct phar-
macological action on serotonergic receptors.
The vortioxetine dose range tested here was chosen to
gradually engage the different serotonergic targets in its
pharmacological proﬁle, which it did in agreement with the
order of in vitro afﬁnities at these receptors in the rat
(Bang-Andersen et al., 2011). Our ex vivo autoradiography
data show that 0.1 mg/kg vortioxetine fully occupied 5-HT3on-induced deﬁcits in NOR performance. 5-HT depletion using
test (Panel A), which were blocked by chronic vortioxetine
ocomotor activity in the NOR task (Panel B). Bars represent
Plus signs (+) and asterisks (*) represent statistically signiﬁcant
Table 2 Target occupancies following acute vortioxetine, ondansetron, and ﬂesinoxan administration in PCPA-treated
female rats. All drugs exhibited a dose-dependent occupancy curve. Values are mean7SEM. N/A—not applicable.
Compound and dose 5-HT1A receptor occupancy (%) 5-HT1B receptor occupancy (%) 5-HT3 receptor occupancy (%)
Vortioxetine
(mg/kg)
0.1 6713 2.274.4 7873.8
3 1575.8 6274.4 9473.8
10 4370.6 8971.9 9771.7
Ondansetron
(mg/kg)
0.001 N/A N/A 9.873.5
1 N/A N/A 2474.7
3 N/A N/A 2575.5
300 N/A N/A 3974.3
1000 N/A N/A 5874.3
Flesinoxan
(mg/kg)
0.1 2874.9 N/A N/A
1.0 2773.9 N/A N/A
2.5 4675.3 N/A N/A
10 8274.4 N/A N/A
25 9372.2 N/A N/A
K.G. du Jardin et al.168receptors in PCPA-treated rats without signiﬁcantly occupy-
ing 5-HT1A or 5-HT1B receptors, and selectively reversed the
5-HT depletion-induced deﬁcit in OR performance without
affecting SA performance. Additionally, 3 and 10 mg/kg
vortioxetine, which occupied 5-HT1B and 5-HT1A receptors
in addition to 5-HT3 receptors, was able to reverse 5-HT
depletion-induced deﬁcits in both OR and SA performance.
4.1. 5-HT3 receptor antagonism reverses 5-HT
depletion-induced memory deﬁcits
Considered in context with the receptor occupancy data,
the selective improvement in OR performance elicited by
vortioxetine 0.1 mg/kg suggests, rather surprisingly, that
5-HT3 receptor antagonism is sufﬁcient to restore normal
object recognition memory in 5-HT-depleted rats. We
considered it unlikely that 5-HT3 antagonism would have
any effect in a 5-HT depletion model such as this. However,
the idea that 5-HT3 antagonism has a beneﬁcial effect under
the conditions used in this study is supported by the potent,
dose-dependent effect of the selective 5-HT3 receptor
antagonist, ondansetron, which also reversed 5-HT deple-
tion-induced deﬁcits in OR performance.
Based on the high level of sequence homology between
5-HT3 receptors and α7 nicotinic receptors, an alternative
explanation for these results may be that the effects of
ondansetron or vortioxetine are mediated via effects on
cholinergic, rather than serotonergic neurotransmission.
However, we regard this alternative mechanism to be highly
unlikely, given the extremely low binding afﬁnity ondanse-
tron has for α7 (Ki=3 μM) and α4β2 (Ki410 μM) nicotinic
receptors (Macor et al., 2001). Additionally, Lundbeck
internal data suggests that vortioxetine has similarly negli-
gible afﬁnity at cholinergic receptors.
It seems implausible that neutral 5-HT3 receptor antago-
nists can improve cognitive function after the 97% depletion
of 5-HT observed in tissue homogenate or 93% depletion in
basal extracellular 5-HT induced by PCPA (Jensen et al.,
submitted for publication). However, we have found thatacute fenﬂuramine administration, which disrupts the vesi-
cular 5-HT storage and reverses the function of SERT (Gobbi
et al., 1998), profoundly increases extracellular 5-HT con-
centrations not only in vehicle-treated animals, but also in
those treated with PCPA (Jensen et al., submitted for
publication). The source of this 5-HT and whether it is
releasable via an impulse ﬂow-dependent mechanism has
yet to be determined. However, these data may suggest
that a biologically signiﬁcant 5-HT pool remains for synaptic
signaling after the PCPA treatment regimen used here. If so,
then it may be possible that the remaining 5-HT is sufﬁcient
to activate 5-HT3 receptors, which could be blocked by a
neutral antagonist such as ondansetron or vortioxetine.
Moreover, the notion that 5-HT3 receptor antagonism can
have beneﬁcial cognitive effects is not novel. Several labora-
tories have reported improved cognitive function in primates
and rodents using ondansetron, particularly where deﬁcits are
induced via manipulation of cholinergic neurotransmission
(Carey et al., 1992; Fontana et al., 1995), glutamatergic neuro-
transmission (Boast et al., 1999), or as the result of aging
(Fontana et al., 1995; Arnsten et al., 1997). Studies in rodents
have also found beneﬁcial effects of ondansetron on memory
function (Petkov et al., 1995; Staubli and Xu, 1995), or
memory-related plasticity measures such as long term potentia-
tion (Staubli and Xu, 1995) in unimpaired animals. Despite the
relatively consistent preclinical literature that 5-HT3 antagon-
ism improves memory function, it is important to note that
ondansetron is viewed as having limited clinical efﬁcacy for
improving cognitive function (Costall and Naylor, 2004),
although beneﬁcial memory effects of ondansetron have been
observed in the clinic (Akhondzadeh et al., 2009; Levkovitz
et al., 2005).
4.2. 5-HT1A receptor agonism reverses 5-HT
depletion-induced memory deﬁcits
Ten milligram per kilogram vortioxetine signiﬁcantly improved
memory in the OR and SA tests, and signiﬁcantly engaged
5-HT3, 5-HT1B and 5-HT1A receptors. The observation that the
1695-HT3 antagonism and 5-HT1A agonism reverse 5-HT depletion induced memory deﬁcitsselective 5-HT1A receptor agonist ﬂesinoxan restored PCPA-
induced memory deﬁcits in both tests could support a role for
5-HT1A receptor agonism in the ability of vortioxetine to reverse
5-HT depletion-induced deﬁcits in OR or SA performance.
Interestingly, 5-HT1A receptor activation appears to have an
“inverted U” type relationship with OR performance, where
1 but not 2.5 mg/kg reversed PCPA-induced deﬁcits. However,
SA performance was improved by both 1 and 2.5 mg/kg doses of
ﬂesinoxan, suggesting that these tests are mediated by distinct
and pharmacologically separable biologies.
It should be noted that preclinical cognition studies in
unimpaired rodents paint a broadly consistent and negative
picture of the effects of 5-HT1A receptor agonists such as
buspirone (Quartermain et al., 1993; Wada and Fukuda,
1992) tandospirone (Quartermain et al., 1993), 8-OH-DPAT
(Stiedel et al., 2000; Pitsikas et al., 2005; Seibell et al.,
2003), and ﬂesinoxan (Herremans et al., 1995; Tsuji et al.,
2003) on learning and memory. However, under conditions
where impairment is induced via scopolamine (Bertrand
et al., 2001) or NMDA receptor antagonism (Horiguchi and
Meltzer, 2012; Depoortere et al., 2010), 5-HT1A receptor
stimulation improves cognitive function.
In the chronic vortioxetine treatment experiment, PCPA
treatment signiﬁcantly impaired performance in the OR task
and chronic vortioxetine treatment blocked these memory
impairing effects, suggesting that vortioxetine’s beneﬁcial
effects on cognitive function in the context of 5-HT deple-
tion are maintained after long periods of administration. In
the SA task, PCPA treatment did not impair performance,
although a nonsigniﬁcant trend towards a reduction was
present. It is likely that this lack of an effect is due to low
statistical power. Likewise, chronic treatment with vortiox-
etine did not signiﬁcantly alter SA performance.
Although we focused on the potential role of 5-HT3 and
5-HT1A receptors in this study, vortioxetine is also active at
other receptor mechanisms over this dose range, which
have not been fully considered here. Our data demonstrate
that vortioxetine occupied meaningful 5-HT1B receptor
occupancy levels over the doses used here. Additionally,
vortioxetine has a similar afﬁnity for 5-HT1A and 5-HT7
receptors, suggesting that 5-HT7 receptor occupancy would
be similar to our observed for 5-HT1A receptor occupancies
over these doses. Therefore, it is possible that 5-HT1B and
5-HT7 receptor mechanisms also play a role in vortioxetine’s
effects on 5-HT depletion-induced memory deﬁcits.
The current study has several limitations that should be
noted. While the data presented here suggest that vortiox-
etine may have some beneﬁcial effects on 5-HT depletion-
induced cognitive dysfunction in rats, it is important to
interpret these results cautiously. First, vortioxetine has an
approximately 10-fold weaker afﬁnity at 5-HT1A and 5-HT7
receptors in rats compared to humans, while it has stronger
effects at the 5-HT3 receptor (Bang-Andersen et al., 2011;
Mørk et al., 2012). Thus it is difﬁcult to extrapolate what
vortioxetine’s effects on MDD-related cognitive dysfunction
in humans will be, based on these data alone. Furthermore,
given that the same animals were used in both the NOR and
SA tasks, it is possible that behavioral history or drug history
altered behavioral responses to the pharmacological treat-
ments used in the SA task. Therefore, these data should be
interpreted with increased caution. Finally, although the
data presented in this manuscript support a role for 5-HT3receptor antagonism and 5-HT1A receptor agonism in
improving OR and SA task performance, we did not attempt
to pharmacologically antagonize these mechanisms in
vortioxetine-treated rats. Thus, we cannot deﬁnitively
assess whether these are the mechanisms by which vortiox-
etine is improving memory performance 5-HT depleted rats.
5. Conclusions
The investigational multimodal antidepressant, vortioxe-
tine, dose-dependently reversed recognition memory and
spatial working memory deﬁcits induced by 5-HT depletion
over a broad dose range, as measured in the NOR and SA
tests. The effect in the NOR test may rely in part on 5-HT3
receptor antagonism, whereas 5-HT1A receptor agonism may
be relevant for both tests. Thus, the memory enhancing
effects of vortioxetine in 5-HT depleted animals may be
ascribed to modulation at 5-HT receptors. These preclinical
results suggest that the clinical potential of vortioxetine’s
effect on cognitive dysfunction in MDD should be explored.
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